ALDOSTERONE, ANGIOTENSIN II AND SYMPATHETIC ACTIVATION IN HYPERTENSIVES

醛固酮、血管紧张素 II 和高血压患者的交感神经激活

• 批准号: 7604843
• 负责人: MARCELO L CORREIA
• 金额: $ 0.04万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-03-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604843
• 关键词: Aldosterone; Angiotensin II; Angiotensins; Antihypertensive Agents; Blood flow; Candesartan Cilexetil; Cardiac Output; Computer Retrieval of Information on Scientific Projects Database; Cross-Over Studies; Double-Blind Method; Forearm; Funding; Grant; Hydrochlorothiazide; Hypertension; Institution; Kidney; Mediator of activation protein; Morbidity - disease rate; Muscle; Nerve; Neurosecretory Systems; Obesity; Outcome Measure; Patients; Plasma; Play; Randomized; Research; Research Personnel; Resources; Risk Factors; Role; Skeletal Muscle; Skin; Source; United States National Institutes of Health; candesartan; cardiovascular risk factor; eplerenone; mortality; relating to nervous system; trafficking

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Increased body mass is an important risk factor for hypertension. Both increased body mass and hypertension independently increase the risk of cardiovascular morbidity and mortality. The mechanisms responsible for the association between obesity and hypertension remain unclear although increased sympathetic nerve traffic to muscles and the kidneys has been implicated. The effectors responsible for the increased sympathetic neural activity in obesity and hypertension remain poorly characterized although elevated plasma aldosterone and angiotensin II are believed to play a major role. We therefore plan to conduct a randomized, double blind, crossover study comparing the effects of aldosterone blockade (with eplerenone), angiotensin II blockade (with candesartan cilexetil, hereafter referred to only as candesartan), combined aldosterone and angiotensin II blockade (using both eplerenone and candesartan), and an antihypertensive agent without aldosterone or angiotensin II antagonism (hydrochlorothiazide) in obese and lean patients with and without hypertension. The secondary outcome measures include the absolute muscle sympathetic nerve activity, skin and total forearm blood flow, skeletal muscle oxygenation, endothelial function, cardiac output, and levels of various neuroendocrine mediators.

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 体重增加是高血压的重要危险因素。体重增加和高血压都会增加心血管疾病的发病率和死亡率。肥胖和高血压之间的联系机制尚不清楚，尽管增加了对肌肉和肾脏的交感神经交通已被牵连。尽管血浆醛固酮和血管紧张素II水平升高被认为起了主要作用，但肥胖症和高血压患者交感神经活性增加的效应机制仍不明确。 因此，我们计划进行一项随机、双盲、交叉研究，比较醛固酮阻滞剂(与依普利酮联合使用)、血管紧张素II阻滞剂(与坎地沙坦酯联合使用，以下仅称为坎地沙坦)、联合应用(使用依普利酮和坎地沙坦)以及不含醛固酮或血管紧张素II拮抗剂的降压药(氢氯噻嗪)对患有高血压和不患有高血压的肥胖和消瘦患者的疗效。次要结果指标包括绝对肌肉交感神经活性、皮肤和前臂总血流量、骨骼肌氧合、内皮功能、心输出量和各种神经内分泌介质水平。